CAR-T In Vitro Efficacy Services with OncoSolid™ Melanoma Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Melanoma Organoid Models

Melanoma is one of the malignant skin cancers, and almost 75% death of skin cancer is related to metastatic melanoma. Melanoma is generated from neural crest stem cells (NCSCs) and can migrate to the brain and lungs, causing an extreme decrease in survival rate in patients. Immunotherapies have been developed to target metastatic melanoma, and proper preclinical models are urgently needed for therapy investigation. Creative Biolabs provides well-established melanoma organoids for routine use as models to predict the response and resistance present in cancer patients.

Workflow

Fig.1 Illustrative workflow of our cancer organoids-mediated in vitro CAR-T efficacy test service. (Zhou, et al., 2021)

Key Features of Our Melanoma Organoid Models

1A living biobank of melanoma organoids, including melanomas with vacuoles, pleomorphic melanomas.

3A digestion-free organoid construction method can be applied to retain the heterogeneity of primary tumors.

2Immune components and stromal cells can be transplanted into organoids.

4PDOs can be established from diverse tumor grades and metastatic status.

Well-characterization of Established Melanoma Organoids

We provide a complete characterization of established melanoma organoids and initial tumor tissue, using recently advanced technologies.

Characteristics	Description
Morphology	Hematoxylin and eosin staining and brightfield images are used to analyze the structure of organoids and primary tumor tissue.
Viability	Staining live/dead cells with specific dyes; measure cell apoptosis using specific antibodies and kits.
Histological Feature	Immunohistochemical staining is applied to detect melanoma-specific biomarkers, such as S100 beta, Melan-A, and tyrosinase, as well as other cell components.
Genetic Mutations	Using multiple omics techniques to study gene mutations, copy-number variations, including top mutant genes, BRAFV600, NRAS, and NF-1.

Screened Tumor Antigen in Patient-derived Organoids

HER2	GD2	VEGFR2	CD20	Gp-100	GPC3	CSPG4	CD70

Cancer Organoid and CAR-T Co-culture Assay

Cancer organoids retain the biological features of tumor tissue and are easy to manipulate. They have become the most popular in vitro models for immunotherapy assessment. We provide the following analysis methods for CAR-T efficacy tests.

T Cell Characterization

T cell activation
T cell cytotoxicity
T cell invasion
Cytokines profiling

Organoid Characterization

Live/dead imaging
Cell apoptosis imaging
Tumor marker detection
Morphology and structure analysis

Related CAR-T Products and Services

Creative Biolabs provides targeted CAR-T products and one-stop CAR-T development services on various cancers, this table shows the melanoma-related targets and corresponding CAR-T products for in vitro anti-tumor function tests using our cancer organoid platform.

Target Antigen	Target Description	CAR-T Products
HER2	HER2 is human epidermal growth factor receptor-2 encoded by the ERBB2 gene and is expressed in melanoma during tumor progression and metastases stages.	Anti-HER2 CAR-T
GD2	GD2, named ganglioside G2 or GRD2, is expressed in many melanoma cells and serves as a potential target for CAR-T therapy.	Anti-GD2 CAR-T
VEGFR-2	Vascular endothelial growth factor-2(VEGFR-2) is present in almost 90% of human melanoma cells and is a proper target for controlling tumor growth.	Anti-VEGFR-2 CAR-T
CD20	Data shows that CD20 is expressed on subtypes of melanomas with stem cell phenotype or tumorigenesis characteristics.	Anti-CD20 CAR-T
Gp100	Gp100 is a type I transmembrane glycoprotein expressed on melanoma cells and is verified as a therapeutic target for uveal melanoma.	Anti-Gp100 CAR-T
GPC3	Glypican-3 (GPC3) is a biomarker of liver cancer and has been demonstrated to be expressed in nearly 40% of melanoma patients.	Anti-GPC3 CAR-T
CSPG4	CSPG4, chondroitin sulfate proteoglycan 4, is a highly antigenic transmembrane proteoglycan expressed on melanoma cells' surface, which affects tumor formation and progression.	Anti-CSPG4 CAR-T
CD70	CD70 is expressed on activated immune cells and primary and metastases melanomas, which involves melanoma invasion function.	Anti-CD70 CAR-T

Case Study

Establishing Patient-derived Melanoma Organoids with the Minimized Process of Tissue
Sampling strategy: Take tumor samples with minimally invasive technology.
Culture condition: Matrigel mediated culture in medium containing DMEM, Hams, F12, MCDB105, FBS, and B27 supplement.
Advantages: Avoid digestion process; retaining the complexity and growth pattern of the primary tumor.
Fig.2 Melanoma organoids retain the histological and immunophenotype features of the parental tumor. (Vilgelm, et al., 2020)

Creative Biolabs offers a high-quality cancer organoids platform for CAR-T efficacy tests. Please contact us and get more detailed information.

References

Vilgelm, A. E.; et al. Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. iScience. 2020, 23(8): 101408.
Zhou, Z.; et al. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.Frontiers in oncology. 2021, 11: 762184.